Építés alatt – nem éles oldal
Belépés
Leállítva2. fázis

A Study of Total Neoadjuvant Chemotherapy With FLOT VS Standard Perioperative FLOT in Patients With Gastric or GEJ Cancer

A legfontosabb adatok

Ki végzi
Baylor College of Medicine
Hol
Houston (Egyesült Államok)Mind a 5 helyszín megnézése
Azonosító
Állapot
Leállítva
Fázis
2. fázis
Résztvevők
3 fő vett részt
Kezdés
2024. márc. 6.
Befejezés
2025. febr. 20.
A vizsgálat típusa
Beavatkozással járó, 2 csoport
A vizsgált kezelések
  • Fluorouracil
  • Leucovorin
  • Oxaliplatin
  • Docetaxel
  • GSCF
A regiszteradat frissítve
2026. április 9.
Miért állt le
Since activation, 3 subjects were enrolled but were ineligible for randomization to a treatment arm because of a positive diagnostic laparoscopy result. Given the repeat inability to enroll and randomize an eligible subject; accrual was halted.

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 23 feltétel megnézéseKevesebb

Ki vehet részt

  • Must provide written informed consent
  • Must be ≥18 years of age
  • Must have life expectancy of greater than 3 months
  • Must have pathologically proven Siewert type II or III GEJ or gastric adenocarcinoma from the main tumor or local lymph nodes (pre-neoadjuvant chemo)
  • Stage cT2 or higher, any N and M0, are eligible for the study
  • M0 disease must be established by both negative distant metastatic disease on imaging AND negative diagnostic laparoscopic assisted cytology of peritoneal fluid cytology not more than 42 days before registration
  • Must be a candidate for neoadjuvant chemotherapy
  • Must be a candidate for curative surgical approach
  • Must have an ECOG performance status 0-2
  • Male or female subjects of childbearing potential must be willing to use contraceptive precautions throughout the trial and for 3 months after discontinuation of study treatment. Female subjects of childbearing potential must have a negative pregnancy test within 28 days of registration. Post-menopausal women must be amenorrhoeic for at least 12 months to be considered of non-childbearing potential
  • Must have adequate kidney, liver, and bone marrow function, within 28 days prior to registration, as follows:
  • Hemoglobin ≥ 8.0 gm/dL (PRBC transfusion is allowed to meet this criteria) ii. Absolute neutrophil count (ANC) ≥ 1000 cells/mm3 iii. Platelet count ≥ 100,000 /mm3 iv. Total bilirubin ≤ 1.5 times upper limit of normal (ULN) v. AST (SGOT) and ALT (SGPT) ≤ 3.0 times the ULN vi. Patient must have adequate renal function as evidenced by one of the following: Serum creatinine ≤ IULN OR calculated creatinine clearance ≥ 60 mL/min. This serum creatinine result must be obtained within 28 days prior to registration
  • Subjects who have required a short course urgent single modality non curative radiation treatment or gastric artery embolization for the purpose of tumor bleeding control are eligible

Ki nem vehet részt

  • Prior chemotherapy for gastric cancer or GEJ cancer
  • Positive cytology or histology for metastatic disease on diagnostic laparoscopy peritoneal fluid. Reports such as: "cannot rule out malignancy" or "suspicious for malignancy, but not definitive" will exclude the subject from enrolling
  • Seiwert type I GEJ cancer
  • Subjects with clinical evidence of metastatic disease
  • Biopsy proven metastatic disease (excluding regional lymph nodes)
  • No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, current non-advanced prostate cancer per the discretion of the investigator, and any other cancers from which the patient has been disease free for two years
  • Any medical condition that, in the opinion of the investigator, would exclude the subject from participating in this study and treatment plan
  • Female subjects who are pregnant, breast feeding, or of childbearing potential with a positive pregnancy test prior to baseline. Women of childbearing potential must have a negative serum pregnancy test as a part of eligibility within 28 days of registration. A persistent positive or elevated urine or blood Beta HCG test may be contributed to the primary diagnosis of GC or GEJ cancer after ruling out ectopic and intrauterine pregnancy and germ cell tumors
  • Subjects unwilling or unable to comply with the protocol or provide written informed consent
  • ECOG > 2

Helyszínek itt: Egyesült Államok

  • Baylor College of MedicineHouston, Egyesült Államok
  • Baylor College of Medicine Medical Center - McNair CampusHouston, Egyesült Államok
  • Baylor St. Luke's Medical CenterHouston, Egyesült Államok
  • Ben Taub HospitalHouston, Egyesült Államok
  • Harris Health System - Smith ClinicHouston, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

This is a randomized pilot study to evaluate and to compare the completion rates of Total Neoadjuvant chemotherapy with FLOT ( FLOT-TNT) and perioperative chemotherapy with FLOT ( FLOT-POP).

A vizsgálat 2 csoportja

  • Arm A: FLOT-TNT ( Investigational Arm)A vizsgált kezelés

    Arm A is the investigational arm with all 4 cycles of FLOT given as total neoadjuvant chemotherapy prior to surgery. Each cycle is 28 days and consists of 2 chemotherapy sessions given every 14 days. The total number of chemotherapy sessions in Arm A is 8. Every effort will be made to have surgery in week 20 ( -1 to +2 weeks), 4 weeks post C4 on arm A.

    Kezelés: Fluorouracil, Leucovorin, Oxaliplatin, Docetaxel és GSCF

  • Arm B: FLOT-POP ( Standard Arm)A vizsgált kezelés

    Arm B us the standard perioperative arm with 2 cycles of pre-operative FLOT ( 4 treatment sessions) and 2 cycles ( 4 treatment sessions) of post-operative FLOT. Post-surgery FLOT will start 4-6 weeks post surgery. Each cycle of chemotherapy consists of 28 days and consists of 2 chemotherapy sessions given every 14 days. The total number of chemotherapy sessions in arm B is 8. Every effort should be done to have surgery done in week 12 ( -1 to +2 weeks) post completion of cycle 2 on ARM B.

    Kezelés: Fluorouracil, Leucovorin, Oxaliplatin, Docetaxel és GSCF

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Randomized, Open Labeled Phase II Pilot Study of Total Neoadjuvant Chemotherapy With FLOT ( FLOT-TNT) VS Standard Perioperative FLOT ( FLOTPOP) in Patients With Gastric or GEJ Cancer, and Assessment of CTDNA as Correlative Biological Response
A regiszteradat frissítve
2026. április 9.